GLENVIEW, Ill., Dec. 02, 2016 -- Illinois Tool Works Inc. (NYSE:ITW) today provided an update on the company’s Enterprise Strategy, including the progress it has made since introducing the strategy in 2012 and future performance goals. The Enterprise Strategy was established to capitalize on the performance power of ITW’s highly differentiated and proprietary business model to generate solid growth with best-in-class margins and returns on capital.
Through the continued execution of its strategy, ITW expects to deliver the following performance goals by the end of 2018 and beyond:
- Organic growth at 200 basis points or more above market;
- 25+ percent operating margin (previously 23+ percent);
- 20+ percent after-tax Return on Invested Capital;
- Free cash flow of 100+ percent of net income; and
- 12 to 14 percent total shareholder returns.
ITW also initiated 2017 guidance at the event and expects earnings per share to be in the range of $6.00 to $6.20, up 9 percent year-over-year at the midpoint, as well as organic growth between 1.5 to 3.5 percent. Additionally, the company reaffirmed its 2016 guidance.
“Even though ITW’s performance is nearing best-in-class levels, we see significant opportunity for further improvement before the Company is operating at its full potential,” said Chairman and CEO, E. Scott Santi. “Through our focus on leveraging the ITW Business Model to its full potential, we are positioning ITW to deliver highly differentiated long term performance and returns.”
Forward-looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding diluted earnings per share, organic revenue growth, operating margin, free cash flow and after-tax return on invested capital. These statements are subject to certain risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated. Such factors include those contained in ITW's Form 10-K for 2015 and Form 10-Q for the third quarter of 2016.
About ITW
ITW (NYSE:ITW) is a Fortune 200 global multi-industrial manufacturing leader with revenues totaling $13.4 billion in 2015. The company’s seven industry-leading segments leverage the unique ITW Business Model to drive solid growth with best-in-class margins and returns in markets where highly innovative, customer-focused solutions are required. ITW has more than 51,000 dedicated colleagues in operations around the world who thrive in the company’s unique decentralized and entrepreneurial culture. To learn more about the company and the ITW Business Model, visit www.itw.com.
Investors Contact: Mike Drazin 224.661.7433 [email protected] Media Contact: Mallory Ramp 224.661.7431 [email protected]


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



